Last reviewed 2026-04-23 · How we verify

BMS-986368

BMS-986368 is an anti-PD-1 monoclonal antibody.

BMS-986368 is an anti-PD-1 monoclonal antibody. Used for Non-small cell lung cancer, Melanoma.

At a glance

Mechanism of action

BMS-986368 works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thereby unleashing an immune response against cancer cells. This mechanism is thought to be effective in various types of cancer.

Approved indications

• Non-small cell lung cancer
• Melanoma

Common side effects

• Fatigue
• Diarrhea
• Nausea
• Rash
• Pruritus

Key clinical trials

• A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity (PHASE2)
• Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease (PHASE2)
• A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity (PHASE1)
• A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants (PHASE1)
• A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants (PHASE1)
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• BMS-986368 CI brief — competitive landscape report
• BMS-986368 updates RSS · CI watch RSS
• Celgene portfolio CI